

Supplemental Table S1 – Additional details about study cohort**Count in visits by follow-up years**

| Year | Variables | Total Cohort | LN | No LN |
|------|--|----------------|----------------|--------------|
| | | N (%) | N (%) | N (%) |
| 1 | N | 601 | 179 | 422 |
| | Hydroxychloroquine (%) | 584 (97.17%) | 163 (99.39%) | 407 (96.45%) |
| | Minimal oral Corticosteroid use (%) | 354 (58.9%) | 88 (53.66%) | 278 (65.88%) |
| | IV Corticosteroid use (%) | 68 (11.31%) | 28 (15.64%) | 40 (9.48%) |
| | Oral Corticosteroid dose (mg/day) | 5 (0, 15) | 10 (0, 30) | 0 (0, 10) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0.07 (0, 0.29) | 0.19 (0, 0.52) | 0 (0, 0.22) |
| | Immunosuppression therapy | 287 (47.75%) | 102 (56.98%) | 185 (43.84%) |
| | Use of low-CS | 346 (57.57%) | 77 (46.95%) | 274 (64.93%) |
| 2 | N | 490 | 164 | 326 |
| | Hydroxychloroquine (%) | 479 (97.76%) | 114 (99.13%) | 316 (96.93%) |
| | Minimal oral Corticosteroid use (%) | 353 (72.04%) | 68 (59.13%) | 265 (81.29%) |
| | IV Corticosteroid use (%) | 56 (11.43%) | 33 (20.12%) | 23 (7.06%) |
| | Oral Corticosteroid dose (mg/day) | 0 (0, 10) | 5 (0, 20) | 0 (0, 5) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0 (0, 0.16) | 0.1 (0, 0.52) | 0 (0, 0.1) |
| | Immunosuppression therapy | 259 (52.86%) | 89 (54.27%) | 170 (52.15%) |
| | Use of low-CS | 339 (69.18%) | 55 (47.83%) | 262 (80.37%) |
| 3 | N | 352 | 115 | 237 |
| | Hydroxychloroquine (%) | 350 (99.43%) | 88 (100%) | 236 (99.58%) |
| | Minimal oral Corticosteroid use (%) | 262 (74.43%) | 50 (56.82%) | 194 (81.86%) |
| | IV Corticosteroid use (%) | 32 (9.09%) | 18 (15.65%) | 14 (5.91%) |
| | Oral Corticosteroid dose (mg/day) | 0 (0, 8) | 1 (0, 20) | 0 (0, 5) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0 (0, 0.13) | 0.02 (0, 0.37) | 0 (0, 0.1) |
| | Immunosuppression therapy | 170 (48.3%) | 56 (48.7%) | 114 (48.1%) |
| | Use of low-CS | 241 (68.47%) | 41 (46.59%) | 186 (78.48%) |
| 4 | N | 251 | 88 | 163 |

| | | | | |
|---|--|----------------|----------------|----------------|
| | Hydroxychloroquine (%) | 247 (98.41%) | 42 (100%) | 159 (97.55%) |
| | Minimal oral Corticosteroid use (%) | 167 (66.53%) | 19 (45.24%) | 117 (71.78%) |
| | IV Corticosteroid use (%) | 34 (13.55%) | 18 (20.45%) | 16 (9.82%) |
| | Oral Corticosteroid dose (mg/day) | 0 (0, 10) | 0.5 (0, 10) | 0 (0, 10) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0 (0, 0.17) | 0.01 (0, 0.19) | 0 (0, 0.14) |
| | Immunosuppression therapy | 101 (40.24%) | 37 (42.05%) | 64 (39.26%) |
| | Use of low-CS | 151 (60.16%) | 16 (38.1%) | 110 (67.48%) |
| 5 | N | 136 | 42 | 94 |
| | Hydroxychloroquine (%) | 134 (98.53%) | 22 (100%) | 92 (97.87%) |
| | Minimal oral Corticosteroid use (%) | 99 (72.79%) | 14 (63.64%) | 80 (85.11%) |
| | IV Corticosteroid use (%) | 27 (19.85%) | 11 (26.19%) | 16 (17.02%) |
| | Oral Corticosteroid dose (mg/day) | 0 (0, 8.5) | 8 (0, 15) | 0 (0, 5) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0 (0, 0.16) | 0.16 (0, 0.24) | 0 (0, 0.1) |
| | Immunosuppression therapy | 67 (49.26%) | 26 (61.9%) | 41 (43.62%) |
| | Use of low-CS | 83 (61.03%) | 9 (40.91%) | 67 (71.28%) |
| 6 | N | 82 | 22 | 60 |
| | Hydroxychloroquine (%) | 79 (96.34%) | 11 (100%) | 57 (95%) |
| | Minimal oral Corticosteroid use (%) | 62 (75.61%) | 8 (72.73%) | 48 (80%) |
| | IV Corticosteroid use (%) | 25 (30.49%) | 11 (50%) | 14 (23.33%) |
| | Oral Corticosteroid dose (mg/day) | 2.75 (0, 7) | 0 (0, 20) | 3 (0, 5) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0.05 (0, 0.13) | 0 (0, 0.44) | 0.06 (0, 0.13) |
| | Immunosuppression therapy | 46 (56.1%) | 12 (54.55%) | 34 (56.67%) |
| | Use of low-CS | 46 (56.1%) | 8 (72.73%) | 37 (61.67%) |
| 7 | N | 35 | 11 | 24 |
| | Hydroxychloroquine (%) | 32 (91.43%) | 12 (100%) | 21 (87.5%) |
| | Minimal oral Corticosteroid use (%) | 27 (77.14%) | 6 (50%) | 19 (79.17%) |
| | IV Corticosteroid use (%) | 9 (25.71%) | 3 (27.27%) | 6 (25%) |
| | Oral Corticosteroid dose (mg/day) | 0 (0, 7.5) | 0 (0, 10) | 0 (0, 6.25) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0 (0, 0.14) | 0 (0, 0.18) | 0 (0, 0.14) |

| | | | | |
|----|--|-------------|-------------|----------------|
| | Immunosuppression therapy | 23 (65.71%) | 5 (45.45%) | 18 (75%) |
| | Use of low-CS | 21 (60%) | 6 (50%) | 13 (54.17%) |
| 8 | N | 24 | 12 | 12 |
| | Hydroxychloroquine (%) | 23 (95.83%) | 8 (100%) | 11 (91.67%) |
| | Minimal oral Corticosteroid use (%) | 18 (75%) | 8 (100%) | 12 (100%) |
| | IV Corticosteroid use (%) | 10 (41.67%) | 6 (50%) | 4 (33.33%) |
| | Oral Corticosteroid dose (mg/day) | 0 (0, 6.5) | 5 (0, 20) | 0 (0, 0) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0 (0, 0.06) | 0 (0, 0.39) | 0 (0, 0) |
| | Immunosuppression therapy | 12 (50%) | 1 (8.33%) | 11 (91.67%) |
| | Use of low-CS | 14 (58.33%) | 8 (100%) | 8 (66.67%) |
| 9 | N | 13 | 8 | 5 |
| | Hydroxychloroquine (%) | 13 (100%) | 5 (100%) | 5 (100%) |
| | Minimal oral Corticosteroid use (%) | 13 (100%) | 4 (80%) | 5 (100%) |
| | Oral Corticosteroid dose (mg/day) | 0 (0, 0) | 0 (0, 0) | 3 (0, 3) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0 (0, 0) | 0 (0, 0) | 0.06 (0, 0.06) |
| | Immunosuppression therapy | 8 (61.54%) | 3 (37.5%) | 5 (100%) |
| | Use of low-CS | 13 (100%) | 3 (60%) | 5 (100%) |
| 10 | N | 9 | 5 | 4 |
| | Hydroxychloroquine (%) | 9 (100%) | 2 (100%) | 4 (100%) |
| | Minimal oral Corticosteroid use (%) | 8 (88.89%) | | 4 (100%) |
| | IV Corticosteroid use (%) | 1 (11.11%) | 1 (20%) | |
| | Oral Corticosteroid dose (mg/day) | 0 (0, 2) | 0 (0, 0) | 1 (0, 2.5) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0 (0, 0.04) | 0 (0, 0) | 0.02 (0, 0.05) |
| | Immunosuppression therapy | 4 (44.44%) | 1 (20%) | 3 (75%) |
| | Use of low-CS | 7 (77.78%) | | 4 (100%) |
| 11 | N | 3 | 2 | 1 |
| | Hydroxychloroquine (%) | 3 (100%) | 2 (100%) | 1 (100%) |
| | Minimal oral Corticosteroid use (%) | 1 (33.33%) | | 1 (100%) |
| | Oral Corticosteroid dose (mg/day) | 20 (0, 40) | 30 (20, 40) | 0 (0, 0) |

| | | | | |
|--|--|----------------|-------------------|----------|
| | Weight adjusted daily oral CS dose (mg/kg) | 0.18 (0, 0.37) | 0.28 (0.18, 0.37) | 0 (0, 0) |
| | Immunosuppression therapy | 2 (66.67%) | 1 (50%) | 1 (100%) |
| | Use of low-CS | 1 (33.33%) | | 1 (100%) |

Count in person-year by follow-up years

| Year | Variables | Total Cohort | LN | No LN |
|------|--|----------------|----------------|--------------|
| | | N (%) | N (%) | N (%) |
| 1 | N | 157 | 42 | 115 |
| | Hydroxychloroquine (%) | 153 (97.45%) | 42 (100%) | 111 (96.52%) |
| | Minimal oral Corticosteroid use (%) | 131 (83.44%) | 30 (71.43%) | 101 (87.83%) |
| | IV Corticosteroid use (%) | 21 (13.38%) | 7 (16.67%) | 14 (12.17%) |
| | Oral Corticosteroid dose (mg/day) | 2 (0, 15) | 12 (0, 27.5) | 0 (0, 10.08) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0.05 (0, 0.31) | 0.29 (0, 0.5) | 0 (0, 0.19) |
| | Immunosuppression therapy | 99 (63.06%) | 36 (85.71%) | 63 (54.78%) |
| | Use of low-CS | 129 (82.17%) | 30 (71.43%) | 99 (86.09%) |
| 2 | N | 141 | 41 | 100 |
| | Hydroxychloroquine (%) | 139 (98.58%) | 41 (100%) | 98 (98%) |
| | Minimal oral Corticosteroid use (%) | 121 (85.82%) | 28 (68.29%) | 93 (93%) |
| | IV Corticosteroid use (%) | 22 (15.6%) | 10 (24.39%) | 12 (12%) |
| | Oral Corticosteroid dose (mg/day) | 1.25 (0, 9) | 5 (0, 20) | 0 (0, 5.61) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0.02 (0, 0.17) | 0.13 (0, 0.46) | 0 (0, 0.1) |
| | Immunosuppression therapy | 95 (67.38%) | 34 (82.93%) | 61 (61%) |
| | Use of low-CS | 120 (85.11%) | 27 (65.85%) | 93 (93%) |
| 3 | N | 114 | 31 | 83 |

| Year | Variables | Total Cohort | LN | No LN |
|------|--|--------------|--------------|-------------|
| | | N (%) | N (%) | N (%) |
| | Hydroxychloroquine (%) | 114 (100%) | 31 (100%) | 83 (100%) |
| | Minimal oral Corticosteroid use (%) | 103 (90.35%) | 26 (83.87%) | 77 (92.77%) |
| | IV Corticosteroid use (%) | 14 (12.28%) | 6 (19.35%) | 8 (9.64%) |
| | Oral Corticosteroid dose (mg/day) | 0 (0, 5) | 0 (0, 13.23) | 0 (0, 5) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0 (0, 0.1) | 0 (0, 0.22) | 0 (0, 0.1) |
| | Immunosuppression therapy | 70 (61.4%) | 24 (77.42%) | 46 (55.42%) |
| | Use of low-CS | 100 (87.72%) | 24 (77.42%) | 76 (91.57%) |
| 4 | N | 83 | 25 | 58 |
| | Hydroxychloroquine (%) | 83 (100%) | 25 (100%) | 58 (100%) |
| | Minimal oral Corticosteroid use (%) | 74 (89.16%) | 19 (76%) | 55 (94.83%) |
| | IV Corticosteroid use (%) | 11 (13.25%) | 6 (24%) | 5 (8.62%) |
| | Oral Corticosteroid dose (mg/day) | 0 (0, 6.25) | 0 (0, 10) | 0 (0, 5.67) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0 (0, 0.12) | 0 (0, 0.18) | 0 (0, 0.1) |
| | Immunosuppression therapy | 41 (49.4%) | 15 (60%) | 26 (44.83%) |
| | Use of low-CS | 71 (85.54%) | 17 (68%) | 54 (93.1%) |
| 5 | N | 47 | 14 | 33 |
| | Hydroxychloroquine (%) | 46 (97.87%) | 14 (100%) | 32 (96.97%) |
| | Minimal oral Corticosteroid use (%) | 39 (82.98%) | 8 (57.14%) | 31 (93.94%) |
| | IV Corticosteroid use (%) | 7 (14.89%) | 2 (14.29%) | 5 (15.15%) |
| | Oral Corticosteroid dose (mg/day) | 0 (0, 7.5) | 2.5 (0, 10) | 0 (0, 5) |

| Year | Variables | Total Cohort | LN | No LN |
|------|--|--------------|----------------|-------------|
| | | N (%) | N (%) | N (%) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0 (0, 0.16) | 0.04 (0, 0.24) | 0 (0, 0.09) |
| | Immunosuppression therapy | 27 (57.45%) | 10 (71.43%) | 17 (51.52%) |
| | Use of low-CS | 36 (76.6%) | 7 (50%) | 29 (87.88%) |
| 6 | N | 26 | 7 | 19 |
| | Hydroxychloroquine (%) | 25 (96.15%) | 7 (100%) | 18 (94.74%) |
| | Minimal oral Corticosteroid use (%) | 23 (88.46%) | 5 (71.43%) | 18 (94.74%) |
| | IV Corticosteroid use (%) | 7 (26.92%) | 2 (28.57%) | 5 (26.32%) |
| | Oral Corticosteroid dose (mg/day) | 0 (0, 5) | 0 (0, 10) | 0 (0, 5) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0 (0, 0.11) | 0 (0, 0.15) | 0 (0, 0.11) |
| | Immunosuppression therapy | 16 (61.54%) | 5 (71.43%) | 11 (57.89%) |
| | Use of low-CS | 19 (73.08%) | 4 (57.14%) | 15 (78.95%) |
| 7 | N | 11 | 3 | 8 |
| | Hydroxychloroquine (%) | 10 (90.91%) | 3 (100%) | 7 (87.5%) |
| | Minimal oral Corticosteroid use (%) | 10 (90.91%) | 2 (66.67%) | 8 (100%) |
| | IV Corticosteroid use (%) | 2 (18.18%) | 1 (33.33%) | 1 (12.5%) |
| | Oral Corticosteroid dose (mg/day) | 0 (0, 6.67) | 0 (0, 13.33) | 0 (0, 6.33) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0 (0, 0.11) | 0 (0, 0.25) | 0 (0, 0.11) |
| | Immunosuppression therapy | 8 (72.73%) | 2 (66.67%) | 6 (75%) |
| | Use of low-CS | 9 (81.82%) | 2 (66.67%) | 7 (87.5%) |
| 8 | N | 10 | 3 | 7 |
| | Hydroxychloroquine (%) | 9 (90%) | 3 (100%) | 6 (85.71%) |

| Year | Variables | Total Cohort | LN | No LN |
|------|--|----------------|----------------|----------------|
| | | N (%) | N (%) | N (%) |
| | Minimal oral Corticosteroid use (%) | 9 (90%) | 2 (66.67%) | 7 (100%) |
| | IV Corticosteroid use (%) | 2 (20%) | 1 (33.33%) | 1 (14.29%) |
| | Oral Corticosteroid dose (mg/day) | 0 (0, 0) | 0 (0, 18.33) | 0 (0, 0) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0 (0, 0) | 0 (0, 0.35) | 0 (0, 0) |
| | Immunosuppression therapy | 7 (70%) | 1 (33.33%) | 6 (85.71%) |
| | Use of low-CS | 8 (80%) | 2 (66.67%) | 6 (85.71%) |
| 9 | N | 4 | 2 | 2 |
| | Hydroxychloroquine (%) | 4 (100%) | 2 (100%) | 2 (100%) |
| | Minimal oral Corticosteroid use (%) | 4 (100%) | 2 (100%) | 2 (100%) |
| | Oral Corticosteroid dose (mg/day) | 0 (0, 1.5) | 0 (0, 0) | 1.5 (0, 3) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0 (0, 0.03) | 0 (0, 0) | 0.03 (0, 0.06) |
| | Immunosuppression therapy | 3 (75%) | 1 (50%) | 2 (100%) |
| | Use of low-CS | 4 (100%) | 2 (100%) | 2 (100%) |
| 10 | N | 4 | 2 | 2 |
| | Hydroxychloroquine (%) | 4 (100%) | 2 (100%) | 2 (100%) |
| | Minimal oral Corticosteroid use (%) | 4 (100%) | 2 (100%) | 2 (100%) |
| | IV Corticosteroid use (%) | 1 (25%) | 1 (50%) | |
| | Oral Corticosteroid dose (mg/day) | 0.83 (0, 3.96) | 3.13 (0, 6.25) | 0.83 (0, 1.67) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0.02 (0, 0.05) | 0.03 (0, 0.06) | 0.02 (0, 0.04) |
| | Immunosuppression therapy | 2 (50%) | 1 (50%) | 1 (50%) |

| Year | Variables | Total Cohort | LN | No LN |
|------|--|----------------|-------------------|----------|
| | | N (%) | N (%) | N (%) |
| | Use of low-CS | 4 (100%) | 2 (100%) | 2 (100%) |
| 11 | N | 2 | 1 | 1 |
| | Hydroxychloroquine (%) | 2 (100%) | 1 (100%) | 1 (100%) |
| | Minimal oral Corticosteroid use (%) | 1 (50%) | | 1 (100%) |
| | Oral Corticosteroid dose (mg/day) | 15 (0, 30) | 30 (30, 30) | 0 (0, 0) |
| | Weight adjusted daily oral CS dose (mg/kg) | 0.14 (0, 0.28) | 0.28 (0.28, 0.28) | 0 (0, 0) |
| | Immunosuppression therapy | 2 (100%) | 1 (100%) | 1 (100%) |
| | Use of low-CS | 1 (50%) | | 1 (100%) |